DaVita (NYSE:DVA) Cut to Hold at Wall Street Zen

Wall Street Zen lowered shares of DaVita (NYSE:DVA) from a buy rating to a hold rating in a research note published on Saturday morning,Wall Street Zen reports.

Other analysts have also issued reports about the company. TD Cowen reissued a “buy” rating on shares of DaVita in a research note on Wednesday, October 21st. Truist Financial cut their price objective on shares of DaVita from $250.00 to $215.00 and set a “hold” rating on the stock in a research report on Friday, August 7th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $265.00 price objective on shares of DaVita in a research note on Wednesday, August 5th. Zacks Research cut DaVita from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Finally, Oppenheimer set a $220.00 price target on shares of DaVita in a research report on Friday, August 7th. Four analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, DaVita currently has an average rating of “Moderate Buy” and an average target price of $235.86.

DaVita Stock Down 1.1%

Shares of DVA opened at $185.37 on Friday. DaVita has a 52-week low of $101.00 and a 52-week high of $247.49. The company has a market capitalization of $11.83 billion, a price-to-earnings ratio of 13.65, a price-to-earnings-growth ratio of 0.48 and a beta of 0.80. The stock has a 50 day moving average price of $181.58 and a 200 day moving average price of $176.90.

DaVita (NYSE:DVA) last released its quarterly earnings results on Thursday, October 29th. The company reported $3.82 EPS for the quarter, beating the consensus estimate of $3.57 by $0.25. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The firm had revenue of $3.58 billion during the quarter, compared to the consensus estimate of $3.52 billion. During the same quarter in the prior year, the firm earned $2.51 EPS. DaVita’s revenue for the quarter was up 4.6% on a year-over-year basis. On average, equities analysts anticipate that DaVita will post 14.74 EPS for the current fiscal year.

Hedge Funds Weigh In On DaVita

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Fifth Third Bancorp grew its stake in DaVita by 831.4% in the first quarter. Fifth Third Bancorp now owns 38,411 shares of the company’s stock worth $5,903,000 after purchasing an additional 34,287 shares in the last quarter. Berkshire Hathaway Inc purchased a new position in shares of DaVita in the 2nd quarter worth approximately $6,425,269,000. Wellington Management Group LLP boosted its stake in DaVita by 305.1% in the second quarter. Wellington Management Group LLP now owns 9,610 shares of the company’s stock valued at $2,138,000 after acquiring an additional 7,238 shares in the last quarter. Assenagon Asset Management S.A. increased its position in shares of DaVita by 30.5% during the second quarter. Assenagon Asset Management S.A. now owns 44,783 shares of the company’s stock worth $9,963,000 after purchasing an additional 10,477 shares in the last quarter. Finally, Wealthfront Advisers LLC acquired a new stake in shares of DaVita in the 2nd quarter worth $2,357,000. 90.12% of the stock is owned by institutional investors and hedge funds.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a health care services company focused on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with chronic kidney failure, including in-center hemodialysis, home dialysis and related clinical support services.

DaVita also offers integrated kidney care programs intended to support patients across the stages of chronic kidney disease. Its services may include care coordination, disease management, education, transplant support and other services designed to improve clinical outcomes and help manage the needs of patients with complex kidney conditions.

The company operates a network of dialysis centers and related facilities in the United States and serves patients in select international markets.